BioSpace News Archive

Silence Therapeutics plc today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.

AIM ImmunoTech Inc. announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® in the treatment of late-stage pancreatic cancer.

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive Actions plan have been submitted to the U.S. Food and Drug Administration.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conference in Las Vegas.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that the U.S. Food and Drug Administration has approved XOLREMDI™ capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.

Leica Biosystems is pleased to announce that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the US Food and Drug Administration.

Henry Schein, Inc. announced today that the Company will present at the following investor conferences in May.

Pfizer Inc. highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4 in Chicago.

Allarity Therapeutics, Inc. today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”).

FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close.